HLB Life Science (067630) Fundamentals 2026 — Revenue Analysis | SniperIQ
HLB Life Science (067630) is a KR-listed Utilities company in Renewable Utilities with a market capitalization of ₩239.7B, trading at ₩1967.00 on the KOE. This SniperIQ fundamentals page covers HLB Life Science's valuation, profitability (net margin -97.7%), revenue (₩45.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is HLB Life Science's market cap?
HLB Life Science (067630) has a market capitalization of approximately ₩239.7B, trading at ₩1967.00 on the KOE. Market cap moves with the live share price.
What is HLB Life Science's P/E ratio?
HLB Life Science's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Utilities sector peers rather than read in isolation.
How profitable is HLB Life Science?
HLB Life Science runs a net profit margin of -97.7%, a gross margin of -4.4%, and an operating margin of -42.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does HLB Life Science generate?
HLB Life Science reported revenue of ₩45.8B for fiscal year 2025, with net income of -₩99.8B and earnings per share (EPS) of -818.99. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does HLB Life Science pay a dividend?
HLB Life Science does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is HLB Life Science financially healthy?
HLB Life Science carries a debt-to-equity ratio of 0.56x and a current ratio of 0.55x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is HLB Life Science a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HLB Life Science (067630) the key facts are: market cap ₩239.7B, revenue ₩45.8B, 52-week range 1608-5330. Weigh valuation, profitability, growth, and balance-sheet strength against Utilities peers and form your own view.
Track HLB Life Science's full fundamentals live
Get HLB Life Science's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.